论文部分内容阅读
脓毒症是外科病人常见的并发症,其实质是失控的炎性反应和凝血紊乱,二者相互影响可导致弥漫性血管内凝血(DIC),进一步发展可出现多器官功能衰竭甚至死亡。尽管祛除病因是治疗脓毒症DIC的根本策略,但在原发病未控制时,药物治疗仍发挥了重要作用。近年来,针对脓毒症DIC的药物治疗研究,尤其是抗凝和抗炎药物的基础及临床试验不断进行,凝血监测手段的进步亦推动了药物治疗的研发及应用。
Sepsis is a common complication in surgical patients. Its essence is uncontrolled inflammatory reaction and clotting disorders. The interaction between the two can lead to disseminated intravascular coagulation (DIC), and further development may lead to multiple organ failure and even death. Although eliminating the cause is the fundamental strategy for the treatment of sepsis DIC, drug treatment still plays an important role in the absence of control of the primary disease. In recent years, the medical treatment of sepsis DIC, especially the basic and clinical trials of anticoagulant and anti-inflammatory drugs, the progress of coagulation monitoring methods also promote the development and application of drug treatment.